INTerpath-009

An aspect marked incomplete is a question the public commentary did not let us answer. We show it rather than hide it.

Screened window

Oct 28, 2024 → Oct 25, 2026

Cited window

Oct 28, 2024 → Oct 25, 2026

Retrieved

Oct 30, 2026

Title

A Phase 3 Randomized Double-blind Study of Adjuvant Pembrolizumab With or Without V940 in Participants With Resectable Stage II to IIIB (N2) NSCLC Not Achieving pCR After Receiving Neoadjuvant Pembrolizumab With Platinum-based Doublet Chemotherapy (INTerpath-009)

Registry

NCT06623422

Study IDs

V940-009 · 2023-506327-29-00 (EU CT) · U1111-1293-5814 (UTN) · INTerpath-009 (MSD) · jRCT2061240105 (jRCT)

Sponsor

Merck Sharp & Dohme LLC

Collaborators

ModernaTX, Inc.

Design

Phase 3 · Interventional, randomized, parallel

Status

Recruiting

Enrollment

680 estimated

Registered

2024-10-02

Start

2024-10-21 actual

Primary completion

2033-05-16 estimated

Primary endpoint

Disease-Free Survival (DFS)

Interventions

8 registered

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

• –Discussion that does not name the trial may be missing from this edition.
• –Some clinician views in the sources used in this report are not yet captured as evidence in this edition.
• –Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
• –60 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
• –Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.
• –This report describes the sources reviewed for this edition, not all HCP views or their prevalence; source and repost counts must not be read as independent clinician counts.
• –No INTerpath-009 efficacy or safety result is provided in the statements. Melanoma efficacy references and KEYNOTE-942 safety figures cannot establish benefit or safety in the target NSCLC population.
• –A full protocol and an exact-trial results publication were not available for this report, and only part of the intervention-related regulatory material was reviewed.
• –Some surrounding discussion of perioperative and neoadjuvant evidence in resectable NSCLC, biomarker testing, specialist capacity and equitable access is not fully represented. This limits the account of the clinical and implementation rationale accompanying cross-study questions.
• –Surrounding melanoma discussion of patient suitability, neoadjuvant feasibility, manufacturing attrition, generalisability, neoantigen validation, control selection and unresolved overall survival is also incomplete; the report should not be read as a complete appraisal of those melanoma studies.
• –Speakers in the podcast and short videos are unnamed. Publisher names, account identities and professional profiles do not establish who spoke those passages.
• –Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.
• –Post dates locate the commentary, not a session or readout. Apart from the explicit clarification within the a speaker–another speaker exchange, dates do not establish changes of mind.
• –Mechanistic, manufacturing and commercial-viability assertions remain attributed views; no comparative evidence is supplied to validate immune-rescue explanations, manufacturing uniformity or broad equitable access.
• –No specific interpretation of the listed secondary endpoints was identified in the material reviewed; this does not establish that such discussion does not exist elsewhere.
• –Not yet captured in this edition: a view on perioperative immunotherapy evidence and testing, capacity, and access barriers in resectable lung cancer.
• –Not yet captured in this edition: a view on perioperative immunotherapy evidence and testing, specialist-capacity and equitable-access barriers in resectable NSCLC.

How reports are built and checked: Methods.

Last checked for new commentary Oct 31, 2026. A new or changed finding gets a new version number; added evidence alone is a smaller update.

Paste this into ChatGPT, Claude, Microsoft Copilot or your own agent. It previews this report through the free Erudio MCP server, tells you whether it answers your question, and orders it if you ask. Some agents ask you to confirm pasted instructions before acting; that is expected.

Help me decide whether to buy the Erudio report "INTerpath-009" (NCT06623422), and buy it for me if I ask. Erudio reports cover what clinicians say in public about one clinical trial, with every verified statement linked to its source.

1. Use the free Erudio MCP server at https://mcp.erudio.com/free; it needs no sign-in. Nothing needs installing: if it is not connected in this app and you can make HTTP requests, call it directly with JSON-RPC POSTs to that URL (initialize, then tools/call), sending "Accept: application/json, text/event-stream". Call get_report_card with slug "interpath-009-06623422". If you cannot make requests, read https://www.erudio.com/reports/interpath-009-nct06623422.md instead.
2. In a few lines, tell me what the report covers: its findings, its verified statements and sources, its evidence window, what it leaves out, and the price of each product (offer). Then ask what I need it for, and say plainly whether this report answers it.
3. If I want it, ask for my work email and the product: the current edition, or 3, 6 or 12 months of weekly updates. Call create_order with report "NCT06623422", that product and email, then show me the quote and the checkout_url to pay by card. If you have a payment client for HTTP 402 payments and I agree, you can pay the pay_url instead. Nothing is charged until one is paid.
4. Once it is paid, call get_order with the status_url: it returns my license key. Then use the Erudio MCP server at https://mcp.erudio.com/mcp with the header "Authorization: Bearer <key>". Call read_report with report_id erudio-nct06623422 and sections ["all"], and summarize the findings for me with their sources. The full report is large (about 500 KB): save the response to a file and work from it rather than printing it. If you cannot, read sections ["narratives"] first, the executive summary and analysis.

When you tell me what clinicians said, give each view as theirs, with its source. Counts are the sources the report kept, not the share of clinicians who agree. Reports are not medical advice.
Keep the key private to my organization.

curl https://www.erudio.com/reports/interpath-009-nct06623422.json
curl https://www.erudio.com/reports/interpath-009-nct06623422.md

# MCP, no sign-in (https://mcp.erudio.com/free)
get_report_card({ "slug": "interpath-009-06623422" })